The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large by Ralston, KJ et al.
The LFA-1-associated Molecule PTA-1 (CD226) on T Cells Forms a
Dynamic Molecular Complex with Protein 4.1G and Human
Discs Large*
Received for publication, January 30, 2004, and in revised form, April 14, 2004
Published, JBC Papers in Press, May 11, 2004, DOI 10.1074/jbc.M401040200
Kylie J. Ralston‡, Samantha L. Hird‡, Xinhai Zhang‡, Judith L. Scott‡, Boquan Jin§,
Rick F. Thorne‡¶, Michael C. Berndt, Andrew W. Boyd**, and Gordon F. Burns‡ ‡‡
From the ‡Cancer Research Unit, School of Biomedical Sciences, The University of Newcastle, University Drive,
Callaghan, New South Wales 2308, Australia, the §Department of Immunology, The 4th Military Medical University,
Xi’an 710032, People’s Republic of China, the Department of Biochemistry and Molecular Biology, Monash University,
Clayton, Victoria 3168, Australia, and the **Division of Cancer and Cell Biology, Queensland Institute of Medical
Research, Royal Brisbane Hospital PO, Brisbane, Queensland 4029, Australia
Clustering of the T cell integrin, LFA-1, at specialized
regions of intercellular contact initiates integrin-medi-
ated adhesion and downstream signaling, events that
are necessary for a successful immunological response.
But how clustering is achieved and sustained is not
known. Here we establish that an LFA-1-associated mol-
ecule, PTA-1, is localized to membrane rafts and binds
the carboxyl-terminal domain of isoforms of the actin-
binding protein 4.1G. Protein 4.1 is known to associate
with the membrane-associated guanylate kinase homo-
logue, human discs large. We show that the carboxyl-
terminal peptide of PTA-1 also can bind human discs
large and that the presence or absence of this peptide
greatly influences binding between PTA-1 and different
isoforms of 4.1G. T cell stimulation with phorbol ester or
PTA-1 cross-linking induces PTA-1 and 4.1G to associate
tightly with the cytoskeleton, and the PTA-1 from such
activated cells now can bind to the amino-terminal re-
gion of 4.1G. We propose that these dynamic associa-
tions provide the structural basis for a regulated molec-
ular adhesive complex that serves to cluster and
transport LFA-1 and associated molecules.
A successful immunological response requires the activation,
proliferation, and differentiation of T cell subsets into effector
cells. These events are initiated by signals generated by sus-
tained interaction between T cell receptors (TCR)1 and antigen-
presenting cells (APC), together with the engagement of acces-
sory counter receptors between the T cell and APC. Without the
coordinated engagement of accessory receptors, engagement of
the TCR can result in T cell anergy (1). Receptor engagement
and signaling appear to be coordinated, both temporarily and
spatially, at a specialized region known as the immunological
synapse (2, 3) increasingly recognized as containing structural
elements shared with classical neuronal synapses (4, 5).
Crucial to the formation of the immunological synapse are
specialized membrane microdomains known as rafts (6) and
also the rearrangement of elements of the cytoskeleton. Both of
these essential components are influenced by receptor engage-
ment at the synapse, and, in turn, both orchestrate molecular
distribution and signal transduction during the interaction
(7–9). An initiating event in synapse formation may be the
migration of intercellular adhesion molecule 3 (ICAM-3) to
sites of cell-cell contact with the APC, where it engages its
counter receptor as part of the “scanning” process (10). Engage-
ment of ICAM-3 results in an increase in intracellular calcium
concentration, the activation of tyrosine kinases, and activa-
tion of the integrin LFA-1 (10, 11). The mechanisms involved in
such “inside-out” activation of leukocyte integrins are complex
and not fully understood (12, 13), but changes in avidity and
affinity of LFA-1 involve clustering in membrane rafts (14–16)
and remodeling of the actin (9, 17) and microtubule (18, 19)
cytoskeleton. Increased intracellular calcium concentration ac-
tivates the small GTPase Rap1, emerging as a major stimulus
for LFA-1 clustering and ligand binding (20–23). Calcium also
activates calpain (24), the proteolytic enzyme that cleaves
talin, a process required for the linkage between integrins and
the actin cytoskeleton that contributes to their clustering and
activation (24–27). Recently, Ginsberg’s group demonstrated
that a phosphotyrosine motif within a  turn of the integrin 
subunit binds to the four point 1/ezrin/radixin/moesin (FERM)
(28) domain contained in the talin head region and exposed by
cleavage from the remainder of the molecule (27, 29).
Subsequently, the TCR and small accessory adhesion recep-
tors migrate to the core of the synapse to form the central
supramolecular activating complex, and larger molecules, in-
cluding LFA-1 and associated talin, are displaced to an outer
adhesive ring, the peripheral supramolecular activating com-
plex (2, 30). These movements may be regulated in part by the
greater numbers of small molecules simply displacing LFA-1
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and other larger molecules within rafts (30). However, larger
adhesion molecules such as CD43, the presence of which might
hinder TCR engagement on physical grounds, are actively ex-
cluded from the synapse by association with ERM proteins (31).
The ERM proteins themselves participate in a number of pro-
cesses essential to T cell activation, including the movement of
adhesion receptors, membrane and cytoskeletal redistribution,
and signal transduction (32–35). Members of an extended pro-
tein 4.1 superfamily, these proteins are characterized by their
possession of a FERM domain toward the amino terminus and
an F actin-binding segment at the carboxyl terminus: in the
resting state, these regions form an intramolecular association
that masks other associations, but following activation by thre-
onine phosphorylation and binding of phosphoinositides, the
tail region is able to extend to bind actin, and the FERM
domain is exposed to bind the juxtamembrane region of any of
several adhesion molecules, thereby providing a transmem-
brane linkage to the actin cytoskeleton (36–39).
The FERM domain of the prototypic protein 4.1R shares
about 30% identity with that of the ERM family members (28)
and shares the capacity to bind transmembrane proteins (40).
In addition, however, this domain of protein 4.1 can bind to
another class of proteins, the membrane-associated guanylate
kinase homologues (MAGUKs) (41). MAGUK family members
contain a number of protein-protein interactive domains, in-
cluding Src homology 3 and PDZ domains, and serve to mediate
the tight clustering of both transmembrane receptors and ion
channels at sites of cell-cell communication such as neuronal
synapses (42). Since the sequence of amino acids in the FERM
domain of 4.1 that binds to transmembrane receptors can differ
from that bound by MAGUKs, these molecules potentially can
form a protein 4.1-transmembrane protein-MAGUK ternary
complex to provide a functional unit at the plasma membrane
with links to the cytoskeleton, and there are now several ex-
amples of such a clustering complex (41, 43). Furthermore,
linkages between these complexes and the cytoskeleton may be
more than passive, since several regulators of small GTPases
contain residues conserved in the 4.1-MAGUK binding site (41,
44, 45).
Recent work from Chishti’s laboratory has raised the excit-
ing possibility that such a MAGUK complex might play a role
in the formation of physical contacts between T cells and APC
and in the regulation of T cell activation, thus extending the
commonalities between the immunological synapse and classi-
cal neuronal synapses (46). This group first identified that in T
cells the MAGUK, human discs large (hDlg), interacts with
both the tyrosine kinase Lck and the potassium ion channel,
Kv1.3 (47). Both Lck and Kv1.3 are known regulators of T cell
signaling and adhesion that may localize to the immunological
synapse (48–50), and hDlg translocates to the lymphocyte cap
upon cross-linking of the CD2 receptor (46). hDlg also associ-
ates with a kinesin-like motor protein termed guanylate ki-
nase-associated kinesin (GAKIN), an association with the po-
tential to drive the microtubule-based trafficking of the
complex to the plasma membrane (46, 51, 52). Moreover, in
different cell types, both MAGUKs and members of the 4.1
family are able to bind transmembrane proteins, thus contrib-
uting to the scaffolding complex (41). In the present study, we
identify a binding partner for the protein 4.1 paralogue, 4.1G,
in T cells, the transmembrane protein PTA-1 (CD226). In ad-
dition, we demonstrate that PTA-1 can bind to hDlg in a proc-
ess requiring its carboxyl-terminal peptide residues, which con-
tain a PDZ-binding motif. We show that PTA-1 binds to the
carboxyl-terminal domain of 4.1G, and the proteins associate
under resting conditions, but, upon stimulation of Jurkat cells,
PTA-1 now can bind to the amino-terminal region of 4.1G and
the complex associates with the cytoskeleton.
PTA-1 (also known as CD226, TLiSA-1, and DNAM-1) is a
member of the immunoglobulin superfamily, the expression of
which is regulated by phorbol ester and calcium (53, 54). Ini-
tially identified as a T cell activation antigen, antibodies and
F(ab)2 fragments against PTA-1 inhibit the development of
cytotoxic T cells and T cell clones from their precursors (55–57).
PTA-1 was also identified on platelets where it may engage in
signal transduction, since anti-PTA-1 monoclonal antibodies
(mAbs) induce platelet activation and aggregation in a process
that requires the Fc receptor (58). Recently Shibuya et al. (59)
showed that PTA-1 was physically and functionally associated
with LFA-1 in NK cells and activated T cells in a process
requiring phosphorylation of a serine residue in the PTA-1
cytoplasmic tail. In addition, cross-linking of LFA-1 induced
tyrosine phosphorylation of PTA-1, possibly mediated by Fyn
with which PTA-1 also associates. Circumstantially, these find-
ings place PTA-1 at the peripheral supramolecular activating
complex of the immunological synapse during T cell activation
and suggest that it may play a role in LFA-1 activation and
downstream signaling. In this study, we additionally show that
PTA-1 associates with Rap-1 in membrane fragments from
activated T cells and that the complex of protein 4.1G, hDlg,
and PTA-1 is contained within membrane rafts.
EXPERIMENTAL PROCEDURES
Antibodies—The LeoA1 (55) and FMU4 (60) mAbs are directed
against PTA-1. Rabbit polyclonal antibodies to 4.1G were raised against
GST fusion proteins containing the amino-terminal domain, 4.1G-Head
(aa 1–115) and the carboxyl-terminal domain, 4.1G-Tail (aa 830–1005).
Affinity-purified IgG was obtained using either GST-4.1G-Head or
GST-4.1G-Tail conjugated to a 1:1 mixture of Affi-gel 10 and 15 (Bio-
Rad) (1 mg of protein/10 ml of resin). Pooled antisera from multiple
bleeds were loaded through the relevant column, and bound IgG was
eluted with 0.1 M glycine, pH 2.4, immediately reneutralized with
one-fifth volume of 1 M Tris, pH 8.0, and dialyzed against Tris saline
buffer, pH 7.4. This affinity-purified antibody was then passed through
a GST-Affi gel 10/15 column to remove IgG against the GST portion of
the fusion protein. The mAb directed against hDlg (2D11) was a gift
from Dr. M. Lutchman (Tufts University School of Medicine, Boston,
MA). The VIIIA7 anti-DAF mAb was a gift from Dr. D. Shafren (De-
partment of Microbiology and Immunology, University of Newcastle).
The Rap1 and calnexin mAbs were purchased from BD Transduction
Laboratories (Lexington, KY). The anti-CD3 mAb (OKT3) was pur-
chased from ATCC.
Cell Lines and Establishment of Permanent Transfectants—The Ju-
rkat T cell line (ATCC) was maintained in RPMI 1640 medium (Thermo
Trace, Melbourne, Australia) containing 10% fetal bovine serum (CSL,
Melbourne, Australia). PTA-1 cDNA was subcloned into the high ex-
pression level eukaryotic vector, pEF-BOS, as described previously (54).
The permanent Jurkat-PTA-1 cell line was established using the Lipo-
fectAMINE™ 2000 reagent (Invitrogen) to introduce a 10:1 excess of the
pEF-BOS-PTA-1 vector (which lacks a eukaryotic selection marker) to
pREP9 (which encodes neomycin phosphotransferase; Invitrogen), fol-
lowed by selection with 750 g/ml G-418 (Invitrogen). The PTA-1-
positive population was verified by flow cytometry and further enriched
by fluorescence-activated cell sorting with the LeoA1 mAb.
The Chinese hamster ovary (CHO) cell line permanently transfected
with PTA-1 (CHO-PTA-1) or DAF (CHO-DAF) were established as
described above and maintained in Dulbecco’s modified Eagle’s medium
(CSL, Melbourne, Australia) with 10% fetal bovine serum. The CHO-
DAF cells were kindly provided by Dr. D. Shafren.
Isolation of Glycolipid-enriched Membranes (GEMs)—These were
prepared as described previously (61). Briefly, Jurkat-PTA-1 cells
(7 107 cells/treatment) were treated with TPA (Sigma) at 50 ng/ml
at 37 °C for varying times, as indicated, or cross-linked with either
LeoA1 or control mAbs followed by rabbit anti-mouse immunoglobu-
lins (RAM) (as described below). Whole cell lysates were solubilized in
1% Triton X-100 in MES-buffered saline, pH 6.5, adjusted to 40%
sucrose and applied under a discontinuous 5–30% sucrose gradient.
Following overnight ultracentrifugation, the GEMs separated as a
low density light-refractive band. The soluble fraction and GEMs
were collected; GEMs were washed and dissolved in MES-buffered
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saline; and the insoluble pellet was further processed by washing
with MES-buffered saline and centrifuged at 14,000  g for 15 min at
4 °C, and then reducing Laemmli sample buffer was added to the
pellet and boiled. Equal protein quantities (15 g) of the GEM and
soluble fractions, along with an equal proportion of the insoluble
pellets, were separated on 7.5% SDS-PAGE and electrotransferred to
nitrocellulose (Sartorius, Germany) using 25 mM Tris, 192 mM gly-
cine, and 20% methanol transfer buffer. To visually determine equal
protein loading, the nitrocellulose membrane was stained with Pon-
ceau S (0.5% Ponceau S, 1% glacial acetic acid) and then washed with
TTBS, followed by immunoblot analysis.
Immunoblotting—Nitrocellulose membranes were blocked in 5%
skim milk in TTBS (25 mM Tris-HCl, pH 8.0, 144 mM NaCl, 0.05%
Tween 20) before incubation with primary antibody in 1% skim milk/
TTBS. Membranes were then incubated with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit immunoglobulins (Bio-Rad),
and the immunocomplexes were detected by enhanced chemilumines-
cence. Between subsequent probes, membranes were stripped by incu-
bation at 60 °C for 30–45 min with 62.5 mM Tris-HCl, pH 6.7, contain-
ing 100 mM 2--mercaptoethanol and 2% SDS.
Cross-linking of PTA-1 Antigen—Jurkat-PTA-1 cells (5  107 cells/
treatment) or CHO-PTA-1 cells (1  107 cells/treatment) were har-
vested by centrifugation or with trypsin-versene solution, respectively,
washed with culture medium, and then resuspended in 1 ml of medium
containing 10 g of LeoA1 or control mAb for 15 min at room temper-
ature. After washing, the cells were either cross-linked with 10 g of
RAM in 1 ml of medium or incubated in medium alone for 15 min at
room temperature. The cells were washed with cold PBS before lysis
and processing for SDS-PAGE analysis.
Immunoisolation of Plasma Membrane Fragments—The method de-
scribed by Harder and Kuhn (62) was used with slight modifications.
Briefly, LeoA1 (anti-PTA-1) and OKT3 (anti-CD3) mAbs were coupled
to M-450 sheep anti-mouse magnetic beads (Dynal), according to the
manufacturer’s instructions. Jurkat-PTA-1 cells (3  107 cells/treat-
ment) were incubated with either the PTA-1- or CD3-coupled beads for
0, 5, and 10 min at 37 °C and then immediately pelleted at 4 °C. The
bead-cell conjugates were washed in H buffer (10 mM Hepes, pH 7.2, 250
mM sucrose, 2 mM MgCl2, 10 mM NaF and 1 mM vanadate supplemented
with CompleteTM protease inhibitors) and then resuspended in 1 ml of
H buffer containing 0.2 mM pervanadate prior to homogenization of the
cells on ice with a glass Dounce homogenizer. The homogenates were
washed with cold H buffer, and the beads were isolated with a magnet
(Dynal), and this was repeated three times. After the final wash, the
proteins were eluted from the beads with reducing Laemmli sample
buffer, separated by SDS-PAGE, and analyzed by immunoblotting.
Yeast Two-hybrid Assay—All MATCHMAKER yeast two-hybrid vec-
tors and cDNA libraries were purchased from Clontech (Palo Alto, CA),
with the exception of the GAL4 DNA binding domain vector,
pGBT9LacZ (a gift of Dr. I. Macreadie, Biomolecular Research Insti-
tute, Parkville, Australia). pGBT9LacZ contains a Trp-selectable
marker and a GAL4-responsive lacZ gene (i.e. additional to that con-
tained in the yeast chromosome), which allows for highly sensitive
detection of interacting proteins by increasing the production of -ga-
lactosidase. The cytoplasmic tail and part of the transmembrane region
of PTA-1 (aa 266–336) was amplified by PCR from human PTA-1 cDNA
using the forward 5-gttgtttgaattctcaattacc-3 and reverse 5-gcataaa-
gatccctgcaggagtac-3 oligonucleotide primers and subcloned to
pGBT9LacZ using the introduced EcoRI and PstI restriction endonu-
clease sites (underlined). The PTA-1 S329F mutant was generated by
PCR amplification of the PTA-1 cDNA using the above forward primer
with a reverse primer 5-ctgcagttaaactctagtctttggtctgcgaAagaaggtt-
gg-3 containing the Ser to Phe mutation (mismatched oligonucleotide
bases are represented in capital letters), along with an introduced PstI
site, and then subcloned to the pGBT9LacZ vector. Similarly, the PTA-1
S329A mutant was constructed using the same forward primer with a
reverse primer containing the Ser to Ala mutation, followed by subclon-
ing to pGBT9LacZ (provided by Dr. P. Sherrington, University of Liv-
erpool, UK). The PTA-1 S329D mutant was generated using the
QuikChangeTM site-directed mutagenesis kit (Stratagene, La Jolla,
CA), with the oligonucleotide pairs 5-gtcaactatccaaccttcGAtcgcagac-
caaagac-3 and 5-gtctttggtctgcgaTCgaaggttggatagttgac-3, both con-
taining the Ser to Asp mutation, with pGBT9LacZ-PTA-1 as template.
All constructs were validated by automated DNA sequencing using an
ABI Prism 377 Automated DNA Sequencer. The MATCHMAKER
cDNA expression libraries were cloned into GAL4 activation domain
vectors containing a leucine (Leu) selectable marker. They consisted of
a human leukemia library produced from unstimulated Jurkat T cell
mRNA containing 2  106 clones, cloned into the pGAD10 vector; the
second was a human brain library encompassing 5  106 clones in the
pACT2 vector.
Transformation and analysis of Saccharomyces cerevisiae HF7c
strain was performed according to the manufacturer’s recommended
protocol (Clontech). Briefly, the yeasts were sequentially transformed
with pGBT9LacZ-PTA-1 and the pGAD10-Jurkat or pACT2-brain
cDNA libraries using the lithium acetate method and plated onto syn-
thetic medium lacking Leu, Trp, and His but containing 15 mM 3-ami-
notriazole (Sigma) and a mixture of galactose, glycerol, and ethanol as
the carbon source. After 4–5 days at 30 °C, colonies were lifted onto
nitrocellulose (MSI, Westbro, MA), incubated facing upward on fresh
medium for 24 h, and, following liquid nitrogen treatment, assayed for
-galactosidase activity by incubation with 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-gal) substrate. pGAD10/pACT2 constructs
from His-positive/-galactosidase-positive colonies were isolated from
the yeast and recovered by electroporation into JM109 cells. Following
small scale plasmid purifications, the cDNAs of potential interactors
were identified by automated DNA sequencing. These constructs were
then reintroduced into the yeast and rescreened for their ability to
interact with pGBT9LacZ-PTA-1 and were quantified using the liquid
-galactosidase assay. For further two-hybrid analysis, pGBT9LacZ-
PTA-1 mutants S329F, S329A, and S329D were screened against the
identified pGAD10-4.1G and assayed as above.
 Phage cDNA Library Screen—A Jurkat T cell cDNA library was used,
which was constructed in the EcoRI site of the  phage vector gt10
(Clontech) and represented 1.1 106 independent clones. The phage were
plated on Escherichia coli Y1090 strain and screened by plaque hybrid-
ization. The DNA probe consisted of the 4.1G cDNA insert isolated from
the yeast two-hybrid library screen, labeled using a high prime DNA
labeling kit (Roche Applied Science). Hybond N membrane (Amersham
Biosciences) lifts were performed in duplicate and were composed of
denaturation (1.5 M NaCl, 0.5 M NaOH) for 7 min, neutralization (1.5 M
NaCl, 0.5 M Tris-HCl, pH 7.5) for 5 min twice, and a 2 SSC rinse followed
by UV cross-linking. The membranes were incubated in prehybridization/
hybridization solution (50% formamide, 5 SSC, 5 Denhardt’s solution,
0.1% SDS, 50 mM NaPO4, pH 6.5, 5 g of herring sperm DNA) for 2 h at
42 °C prior to overnight hybridization with the 32P-labeled 4.1G probe at
42 °C. The filters were washed twice at room temperature in 2 SSC,
0.1% SDS and then in 0.2 SSC, 1% SDS for 60 min at 55 °C, followed by
autoradiography. Positive plaques were isolated from the original plate,
and the bacteriophage eluted in PSB (0.1 M NaCl, 10 mM MgCl2, 10 mM
Tris-HCl, pH 7.4, 0.05% gelatin) overnight at 4 °C. Secondary and tertiary
screens were performed to facilitate the isolation of a single positive clone.
The bacteriophage particles were purified from the PSB eluate, and the
DNA was isolated according to standard procedures. The cDNA insert
was released from the phage vector by EcoRI restriction, subcloned to
pBluescript vector (Promega Corp., Madison, WI), followed by automated
DNA sequencing.
Northern Blot Analysis—Northern blotting was performed as previ-
ously described (54), using total RNA isolated from either resting Jur-
kat cells or Jurkat cells treated with TPA at 50 ng/ml overnight to
induce PTA-1 expression. The DNA probe consisted of the 4.1G cDNA
insert isolated from the yeast two-hybrid screen and radiolabeled as
described above (see  phage library screen). Following autoradiogra-
phy, the filter was reprobed for glyceraldehyde-3-phosphate dehydro-
genase as an RNA loading control.
Immunofluorescent Cell Staining and Confocal Microscopy—CHO-
PTA-1 cells were grown on glass coverslips overnight and then fixed and
permeabilized with cold methanol for 10 min at 20 °C. Dual color im-
munostaining was performed with LeoA1 mAb and 4.1G-Head and 4.1G-
Tail polyclonal antibodies as indicated, followed by detection with a mix-
ture of Alexa 488-conjugated goat anti-mouse and Alexa 594-conjugated
goat anti-rabbit immunoglobulins (Molecular Probes, Inc., Eugene, OR).
The stained coverslips were mounted onto glass slides with ProlongTM
Antifade reagent (Molecular Probes), and the fluorescently labeled cells
were visualized on a Zeiss LSM510 confocal microscope.
For the cytochalasin D experiments, CHO-PTA-1 and CHO-DAF
cells were used. Cells were grown on glass coverslips and treated with
either 2 M cytochalasin D (Sigma) or carrier alone (Me2SO) for 60 min
at 37 °C, followed by fixation with 4% formaldehyde (w/v) in PBS for 15
min at room temperature and permeabilization with 0.3% Triton X-100
in PBS for 5 min at room temperature. The cells were stained with
monoclonal (LeoA1 and VIIIA7) or polyclonal (4.1G-Head) antibodies,
followed by Alexa 594-conjugated goat anti-mouse or anti-rabbit immu-
noglobulins (Molecular Probes), with actin visualized with Alexa 488-
conjugated phalloidin (Molecular Probes). The coverslips were mounted
as above and examined by epifluorescent microscopy on a Zeiss Axio-
plan microscope. The merged images were obtained by overlaying the
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individual images using Adobe PhotoshopTM software.
Construction, Expression, and Purification of GST Fusion Proteins—
The GST-PTA-1 construct containing the PTA-1 carboxyl terminus and
part of the transmembrane region (aa 266–336) was generated by
subcloning the EcoRI restriction fragment from pGBT9LacZ-PTA-1 to
pGEX-2T (Amersham Pharmacia Biotech). The GST-PTA-1TRV con-
struct also contains the same region of PTA-1 but lacks the three
carboxyl-terminal residues Thr, Arg, and Val (aa 266–333), subcloned
to pGEX-4T-3 using EcoRI/NotI restriction sites (provided by Dr. P.
Sherrington). The GST-4.1G-Tail (GST-4.1G-CTD) construct containing
the 175 carboxyl-terminal residues (aa 830–1005) was prepared from
EcoRI restriction of pGAD10–4.1G subcloned to pGEX-2T. The GST-
4.1G-Head construct comprising the 115 amino-terminal residues (aa
1–115) was prepared by PCR amplification of pCDNA3–4.1G-myc (pro-
vided by Dr. P. Gascard, University of California, Berkeley, CA), using
the oligonucleotides 5-gaagtaggatccgtgtctgaag-3 and 5-ggggaattctt-
tatctaagacc-3, and subcloned to pGEX-2T via the introduced BamHI/
EcoRI restriction sites. The GST-RBD construct encodes a GST fusion
to the Rap binding domain (provided by Dr. J. Bos, Utrecht University,
The Netherlands) and has been previously described (63). All constructs
were verified by restriction endonuclease analysis or automated
DNA sequencing.
BL21 (DE3) cells (Stratagene) were transformed with the various
GST constructs, cultured to an A600 of 0.6- 1.0, and recombinant GST
fusion protein expression was induced with 0.1 mM isopropyl-1-thio--
D-galactopyranoside for 4 h. The bacteria were collected by centrifuga-
tion, resuspended in ice-cold PBS containing CompleteTM protease in-
hibitors (Roche Applied Science), and then disrupted by sonication on
ice for 6  10-s pulses. Triton X-100 was added (1% final) and mixed for
30 min at 4 °C, and the soluble and insoluble proteins were separated
by centrifugation at 3000 g for 10 min. The recombinant GST proteins
were purified from the soluble supernatant by incubation with PBS-
washed glutathione-Sepharose 4B beads (Amersham Biosciences) at
4 °C for 2 h. The GST-bead complexes were then washed three times
with PBS. For the pull-down experiments, the GST-bead complexes
were further washed with lysis buffer prior to incubation with cell
lysates. For recombinant GST protein purification, the GST proteins
were eluted with five bed volumes of glutathione elution buffer (10 mM
reduced glutathione in 50 mM Tris-HCl, pH 8, supplemented with
CompleteTM protease inhibitors) at 4 °C, and the beads were removed
by centrifugation. The eluted proteins were evaluated for purity and
integrity by SDS-PAGE and quantified by spectrophotometry.
GST Pull-down Assay—For some experiments, Jurkat cells were
biosynthetically labeled with [35S]cysteine/methionine prior to lysis.
The cells were pelleted, washed in cysteine/methione-free RPMI
(Thermo Trace, Melbourne, Australia), and then starved in the same
medium for 30 min at 37 °C. The cells were then resuspended in this
medium with the addition of 1 mCi of [35S]cysteine/methionine
(PerkinElmer Life Sciences) for 3 h at 37 °C, and TPA (50 ng/ml)
stimulation was continued through the labeling as appropriate. After
washing with PBS, the cells were lysed for 60 min at 4 °C with Nonidet
P-40 lysis buffer (1% Nonidet P-40, 25 mM Tris, pH 7.6, 150 mM NaCl
supplemented with CompleteTM protease inhibitors).
The protein kinase C (PKC) assay kit (Stratagene) was used to
phosphorylate GST-PTA-1, according to the manufacturer’s instruc-
tions. Briefly, the GST-PTA-1-Sepharose bead complexes were washed
in the supplied phosphorylation buffer and then incubated in this buffer
containing 1 mM rATP, diolein and phosphatidyl serine phospholipids,
and PKC (, , and  isoforms) for 10 min at 30 °C. The protein-bead
complexes were washed in radioimmune precipitation assay lysis buffer
and then used in the pull-down assay.
Unless indicated otherwise, Jurkat cells were lysed with radioim-
mune precipitation assay lysis buffer for 60 min at 4 °C. Insoluble
material was removed by centrifugation for 10 min at 14,000  g at
4 °C. Lysates were precleared using GST-alone-coupled Sepharose
beads for 1–2 h at 4 °C and then pulled down with either GST-, PTA-1-,
phosphorylated PTA-1-, or PTA-1TRV-coupled beads as indicated for
1–2 h at 4 °C. The beads were then washed four times in lysis buffer,
eluted with reducing Laemmli sample buffer, and resolved by SDS-
PAGE. Gels containing radiolabeled samples were fixed, Coomassie-
stained, and dried, and the labeled protein bands were visualized by
fluorography. Otherwise, gels were transferred to nitrocellulose and
subjected to immunoblotting.
Immunoprecipitation—Approximately 1.5  108 Jurkat-PTA-1 cells
were treated with TPA (50 ng/ml) for 2 h at 37 °C and then treated with
2 mM cytochalasin D for 60 min at 37 °C. The cells were pelleted and
washed with PBS prior to digitonin (Sigma) lysis (1% digitonin, 20 mM
Hepes, pH 7.5, 150 mM NaCl, with CompleteTM protease inhibitors) for
60 min at 4 °C before clarification by centrifugation 14,000  g. To
reduce nonspecific binding during immunoprecipitation, the lysate was
precleared with the capture reagents alone. Antigens were then immu-
noprecipitated with the specific mAbs (LeoA1; 2D3, a control antibody
that binds to CD47 on the surface of Jurkat cells) indirectly bound by
rabbit anti-mouse immunoglobulins (DAKO) directly coupled to CnBr-
activated Sepharose 4B beads (Amersham Biosciences). Immunocom-
plexes were then washed four times with the digitonin lysis buffer and
then eluted by boiling with reducing Laemmli sample buffer. Samples
were resolved by 7.5% SDS-PAGE, transferred to nitrocellulose, and
then analyzed by immunoblotting.
Surface Plasmon Resonance—The BIACore experiments were per-
formed essentially as described previously (64). In brief, purified GST
and GST-4.1G-Head or Tail (CTD) protein (50 mg/ml) were immobilized
onto CM5 sensor chips (BIACoreTM) by the amine coupling method,
according to the manufacturer’s instructions. The immobilization
yielded 3000 (GST) and 6300 (GST-4.1G-Head, similarly for GST-4.1G-
Tail) resonance units of binding. Purified GST-PTA-1, GST-4.1G-Tail,
and GST-alone proteins (all at 50 g/ml) were passed over the sensor
chips. The very weak binding of GST was subtracted from the GST-
PTA-1 and GST-4.1G-Tail binding to yield the resultant sensorgram.
RESULTS
PTA1 Is Recruited into Membrane Rafts and Associates with
Rap1 and the Cytoskeleton upon Cross-linking—A physical and
functional association between PTA-1 and LFA-1 integrin sug-
gested that PTA-1 may be implicated in the adhesive processes
that occur during T cell activation. Many of the molecules that
engage in the T cell signaling cascade are found to localize in or
be recruited to lipid rafts during the activation process (8). To
examine whether PTA-1 might be contained within rafts, we
used the biochemical approach of isolating the cold Triton
X-100-insoluble material known as GEMs or detergent-insolu-
ble glycolipid structures that may represent raft material (Fig.
1A). Resting T lymphocytes and Jurkat T cells express very
little PTA-1 protein (54); therefore, to facilitate protein detec-
tion, we utilized Jurkat cells stably transfected with PTA-1 for
these assays. However, similar results were obtained with non-
transfected Jurkat cells that had been prestimulated for 30 h
with TPA to induce PTA-1 protein expression and then rested
overnight before restimulation (data not shown; see below). In
these assays, a proportion of PTA-1 from resting cells was
found to localize to the GEM fraction (G in Fig. 1A), indicating
raft-resident status; however, cross-linking of the PTA-1 anti-
gen with anti-PTA-1 mAb followed by rabbit anti-mouse anti-
body (PTA-1  RAM) (Fig. 1A) or stimulation of the cells with
TPA (Fig. 1B) induced an increased proportion of the PTA-1 to
locate to the GEM fraction. The endoplasmic reticulum-resi-
dent protein, calnexin, was used as a control in these experi-
ments and was found predominantly in the soluble fraction (S)
as expected; its distribution was not altered by cell stimulation
(Fig. 1B). In these experiments, it was also found that cross-
linking of PTA-1 resulted in an accumulation of this antigen in
the washed cytoskeletal pellet that had precipitated through
the sucrose gradient (I; Fig. 1A).
Upon cross-linking or cell stimulation with TPA or anti-CD3,
PTA-1 becomes phosphorylated on a serine residue and asso-
ciates with LFA-1 (58, 59). Subsequent LFA-1 engagement and
cross-linking results in the tyrosine phosphorylation of PTA-1
and its association with Lyn PTK (59). These data implicate
PTA-1 in both the regulation of LFA-1 function and further
downstream signaling. Recent work has strongly implicated
Rap1 in the regulation of LFA-1 function (22), and in the
transfected Jurkat cells, we found Rap1 to be a resident of
GEMs (Fig. 1B); therefore, we considered whether PTA-1 might
associate with Rap1. The use of GST-PTA-1 in pull-down ex-
periments did not reveal any direct association (data not
shown); therefore, we employed the method developed by
Harder and Kuhn (62) to analyze plasma membrane subfrag-
ments for associated signaling molecules. Magnetic beads were
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coated with the anti-PTA-1 mAb, LeoA1, or, as a control, with
anti-CD3. These were mixed with PTA-1-transfected Jurkat
cells and warmed at 37 °C for 5 or 10 min before homogeniza-
tion of the cells and immunoisolation of the bound membrane
fragments. Analyzed by immunoblotting, the CD3 fragments
co-purified with several signaling molecules after 5 and 10 min
of cell stimulation (62) (data not shown) but not with Rap1 (Fig.
1C). In contrast, stimulation and immunoprecipitation with the
anti-PTA-1 (LeoA1)-coated beads revealed that Rap1 co-asso-
ciates with PTA-1 in membrane fragments isolated from the
transfected Jurkat cells after PTA-1 cross-linking (Fig. 1C).
This result places Rap1 in the vicinity of PTA-1 and LFA-1 at
the plasma membrane of these cells; other signaling molecules
associated with the complex will be reported elsewhere.
The Cytoplasmic Domain of PTA-1 Binds the Carboxyl-ter-
minal Domain (CTD) of Protein 4.1G—Yeast two-hybrid anal-
ysis was then used to identify PTA-1 binding partners that
might contribute to complex formation. The entire cytoplasmic
region and part of the transmembrane domain of PTA-1 in the
bait vector (Fig. 2A) was used to screen a Jurkat T cell cDNA
library. The entire library of 2  106 independent clones was
screened, and three positive clones were isolated. All three
clones were confirmed as true binding partners when tested
against a range of controls. The three clones were sequenced
and shown to contain the same sequence identified as identical
to the CTD of protein 4.1G (Fig. 2B), a ubiquitous member of
the protein 4.1 family (65). The relative strength of binding
between PTA-1 and the CTD of 4.1G was measured in a liquid
-galactosidase assay, and the well characterized CD4-Lck in-
teraction was measured as a comparative control; CD4-Lck
interaction produced 2.9 -galactosidase units, and the PTA-
1–4.1G produced 91.4 units, indicating strong binding in the
yeast two-hybrid assay. To further validate this result and to
identify additional binding partners, we used the same region
of PTA-1 to screen a second cDNA library. A human brain
library was selected, because PTA-1 is also expressed in certain
brain tissues,2 and 11 positive clones were isolated from screen-
ing 5  106 clones. Validation tests confirmed only one of these
clones to be a true positive, and this was found to encode
exactly the same protein as those isolated from the Jurkat
library. Isolation of this same clone validates the interaction
between PTA-1 and the CTD of 4.1G in this assay, since the
same protein was obtained from four separate clones and two
different libraries.
Parra et al. (65) record that protein 4.1G is generally ex-
pressed in a wide range of tissues but is relatively less abun-
dant than 4.1R in hematopoietic tissues and only weakly ex-
pressed in peripheral leukocytes; therefore, we examined the
expression of 4.1G mRNA in Jurkat cells by Northern blot
analysis. Fig. 2C shows that 4.1G mRNA in these cells appears
as three major transcripts, at approximately 4.1, 4.6, and 7.3
kb. This is very similar to the pattern reported for human brain
but quite different from that obtained in seven other human
tissues where a single prominent transcript at around 5 kb was
obtained (65). The multiple brain transcripts were attributed to
alternative splicing and/or differential use of polyadenylation
sites (65), and in support of alternative splicing in Jurkat cells
we isolated a cDNA from this cell line that showed apparent
differential exon usage from the published sequence of 4.1G
assembled from various EST clones (65) (GenBankTM accession
number AY512660). Since the expression of PTA-1 in Jurkat
cells is induced by TPA at the transcriptional level (65), we also
examined the influence of TPA on the isoforms of 4.1G ex-
pressed in these cells. Fig. 2C illustrates that this treatment
resulted in the down-regulation of the larger transcripts, leav-
ing only the 4.1-kb transcript.
In order to examine 4.1 protein expression, rabbit antibodies
(“tail” antibodies) were raised and affinity-purified against the
CTD of 4.1G in the form of a GST fusion protein and used for
Western blot analyses. These analyses confirmed the presence
of 4.1G protein in the Jurkat cells and also in the CHO cells
used for some immunofluorescent staining experiments (Fig.
2D). The major products identified from the Jurkat cells were
at around 170 kDa, and a lesser band was seen at around 111
kDa. The largest band approximates in size to the major prod-
uct identified from transfected COS cells by Parra et al. (65)
and is larger than the size of 113 kDa predicted from the
cDNA. These different products possibly could exhibit some
post-translational processing, and a smaller band at 110 kDa
was also illustrated by Parra et al. (65) in their transfected
COS cell analysis. Fig. 2D from the Jurkat cell lysate also
reveals the presence of a series of polypeptides ranging from 30
to 173 kDa; whether these represent alternatively spliced prod-
ucts or proteolytic products is not known, but this pattern was
highly reproducible in numerous experiments. Similar results
were obtained with CHO cell lysates analyzed in the same way
(Fig. 2D), although some of the bands differed in Mr from those
of the Jurkat cells. This wide range in polypeptide size was not
entirely unexpected, since 4.1 proteins are reported to display
2 G. F. Burns, unpublished data.
FIG. 1. Cross-linking of PTA-1 results in recruitment to GEMs
and an association with the cytoskeleton and with Rap1-con-
taining plasma membrane fragments. A, Jurkat cells stably trans-
fected with PTA-1 were treated with mAb (anti-PTA-1 or control) alone
or by further cross-linking with rabbit anti-mouse antibodies (anti-
PTA-1  RAM; control  RAM) for 15 min before lysis in cold Triton
X-100 and centrifugation through a sucrose gradient. Immunoblotting
(IB) for PTA-1 was performed on equal protein loadings of the visible
GEM band (G) and the soluble material (S) containing the bulk of the
protein, together with an equivalent proportion of the washed insoluble
cytoskeletal pellet (I). Note that the soluble fraction contains over 90%
of the total protein content; therefore, because of equal protein loading,
PTA-1 contained in this fraction is greatly diluted and yields a low
signal. Note also that PTA-1 is represented by the diffuse band at
around 64 kDa; the tight band below (*) is a nonspecific band that was
sometimes observed in immunoblots for PTA-1. As a control, identical
samples were immunoblotted for the endoplasmic reticulum protein
calnexin. B, PTA-1-transfected Jurkat cells were stimulated with TPA
as indicated, and cell lysates were separated on sucrose gradients as in
A. The GEM fractions and protein equivalents of the soluble fractions
were immunoblotted for PTA-1, calnexin, and Rap1. C, immunoblotting
for Rap1 shows association with the plasma membrane fragments im-
munoisolated with anti-PTA-1-coated magnetic beads but not with anti-
CD3-coated beads after 5 and 10 min of cross-linking at 37 °C.
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extensive diversity in molecular weight, with one Western blot
study revealing 4.1 immunoreactive proteins ranging in size
from 30 to 210 kDa (66). Nevertheless, because the CTD of 4.1G
bound by PTA-1 in the yeast two-hybrid system that was also
used for immunization shares some 60% identity with the same
region of 4.1R, it was important to establish that each of the
immunoreactive bands represented 4.1G and not cross-reactive
4.1R or another 4.1 family member. To accomplish this, rabbit
antibodies were raised and affinity-purified against a GST
fusion protein incorporating only the first 115 aa residues that
are unique to 4.1G (“head” antibody). Used directly for Western
blotting of Jurkat (Fig. 2E) or CHO (data not shown) cell
lysates or in reciprocal immunoprecipitation and blotting ex-
periments, both the “head” and the “tail” antibodies yielded
similar results, thereby validating the status of the multiple
4.1G polypeptides (Fig. 2, compare D and E); however, in im-
munofluorescent experiments with CHO cells, the “tail” but not
the “head” antibodies did exhibit intranuclear staining, indi-
cating some 4.1R immunoreactivity (data not shown). In the
blotting experiments with both “head” (Fig. 2E) and “tail” (data
not shown) antibodies, it was found that stimulation of the
Jurkat cells with TPA did not alter the profile of putative
isoforms obtained (Fig. 2E).
We then utilized these antibodies to seek to identify a phys-
ical in vivo association between PTA-1 and 4.1G. CHO cells
stably transfected with PTA-1 were used in these experiments,
and good co-localization was seen at the plasma membrane
between PTA-1 and 4.1G detected with either “head” or “tail”
antibodies (Fig. 3A). Protein 4.1 contains a spectrin/actin-bind-
ing domain and might be expected to associate with actin,
particularly at the submembranous skeleton at the plasma
membrane. To visualize this, permeabilized transfected CHO
cells were incubated with Alexa 488-phalloidin to illuminate F
actin and also stained for 4.1G (Fig. 3B). Some degree of co-
localization was obtained, but this was much more evident
after the actin cables were disrupted by treatment with cy-
tochalasin D causing the fibers to collapse into a pronounced
lumpy appearance. After such treatment, 4.1G staining was
found to be coincident with the areas of condensed actin (Fig.
3B). Co-staining of cells for DAF (CD55) did not reveal coinci-
dence of staining with phalloidin before or after cytochalasin
treatment, whereas staining for PTA-1 showed close coinci-
dence of staining with phalloidin after treatment (Fig. 3B).
It was noted above that upon antibody-mediated cross-link-
ing of PTA-1 on Jurkat cells, a proportion of the PTA-1 was
found to precipitate with the cytoskeleton (see Fig. 1A). There-
fore, we questioned whether this might also occur in the trans-
fected CHO cells and, if so, whether this distribution of 4.1G
FIG. 2. The cytoplasmic domain of
PTA-1 interacts with the carboxyl-
terminal domain of 4.1G that is ex-
pressed in Jurkat T cells. A, depiction
of the amino acid sequence of PTA-1 in-
corporated into the pGBT9LacZ Y2H bait
vector. B, schematic of 4.1G showing the
major functional domains. SABD, spec-
trin actin-binding domain. The position of
the 4.1G cDNA clones isolated in the two-
hybrid assays against PTA-1 are under-
lined. C, Northern blot for 4.1G in resting
Jurkat cells and Jurkat cells stimulated
with TPA overnight. The filters were
stripped and reprobed for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). D,
immunoblot (IB) of CHO and Jurkat cell
lysates with preimmune rabbit serum
(control) or with affinity-purified rabbit
antibodies raised against the CTD of 4.1G
(4.1G-Tail). E, immunoblot of Jurkat cell
lysates with affinity-purified antibodies
raised against the ATD of 4.1G (4.1G-
Head). Cells were untreated (0) or stimu-
lated with TPA for 10 min or 16 h before
analysis.
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was also influenced by such cross-linking. PTA-1-transfected
CHO cells were treated with anti-PTA-1 mAb (or control) and
then cross-linked with RAM before lysis and centrifugation of
the postnuclear supernatant to isolate the cytoskeletal pellet.
Immunoblotting for PTA-1 showed that after specific cross-
linking a large proportion of the PTA-1 antigen now pelleted
with the cytoskeleton, indicating a tight association (Fig. 3C).
Reblotting the same samples for 4.1G revealed that a propor-
tion of this protein pelleted with the cytoskeleton in the resting
CHO cells; however, this proportion was increased following
cross-linking of PTA-1 (Fig. 3C). These results show that cross-
linking of PTA-1 on the cell surface can influence the distribu-
tion of 4.1G, further substantiating an association between
the molecules.
The Carboxyl-terminal Peptide of PTA-1 Binds the MAGUK,
Human Discs Large—As we documented in the Introduction,
members of the protein 4.1 family are found to associate with
MAGUKs, which play an important role in assembling signal
transduction complexes at the interface of the membrane cy-
toskeleton (67). MAGUKs contain one or more PDZ domains
that engage in protein-protein interactions, including binding
to the carboxyl-terminal peptides of some transmembrane pro-
teins. The carboxyl terminus of PTA-1 terminates in the se-
quence Lys-Thr-Arg-Val (KTRV), a recognized PDZ-binding
motif; therefore, we determined whether this region of PTA-1
engaged in protein binding. For this, we prepared GST fusion
proteins encoding the entire cytoplasmic tail of PTA-1 or the
PTA-1 tail lacking the three terminal residues, TRV (PTA-
1TRV). These were used in pull-down experiments with ly-
sates of resting or TPA-stimulated Jurkat cells that had been
prelabeled with [35S]Cys/Met. The fluorographs obtained re-
vealed several polypeptides that bound to GST-PTA-1 but not
to GST alone (Fig. 4A), indicating specific binding. Comparison
of the specific bands precipitated by PTA-1 versus PTA-1TRV
identified several differences, including one polypeptide at
around 21 kDa that, intriguingly, was more prominent in the
PTA-1TRV precipitate (Fig. 4A). The identity of this band is
not known, but this result indicates that the carboxyl-terminal
peptides can influence PTA-1-protein binding, possibly either
by direct binding to a PDZ-containing protein that blocks bind-
ing to another site or by virtue of a particular conformation.
Two bands in particular were prominent in the PTA-1 pull-
downs that were negligible or absent in the pull-downs with
PTA-1TRV; notably, these bands were also more prominent
from lysates of Jurkat cells that had been stimulated with
TPA-1 (Fig. 4A).
Either of these two bands might represent binding to a
PDZ-containing protein, and we focused on the band at around
110 kDa (Fig. 4A, arrow) because this approximates the migra-
tion of hDlg in SDS-PAGE, and hDlg has been shown to asso-
ciate with protein 4.1R in epithelial cells (52). Further pull-
down experiments were therefore carried out with the PTA-1
and PTA-1TRV proteins and tested by immunoblotting for
hDlg; in addition, since PKC-mediated phosphorylation of
PTA-1 has been implicated in its function (68), we also tested
binding to the GST-PTA-1 protein that had been subjected to
PKC-mediated phosphorylation in vitro (PKC). The results
obtained are shown in Fig. 4B, where it is apparent that GST-
PTA-1 can bind to hDlg. Binding is modestly increased after
phosphorylation of the GST-PTA-1 by PKC, but removal of the
terminal TRV peptide residues from PTA-1 almost abolishes
binding of hDlg, with the small residual binding perhaps being
attributable to a ternary complex (Fig. 4B). To confirm that
PTA-1 associates with hDlg in vivo, we carried out co-precipi-
tation analyses from TPA-stimulated Jurkat PTA cells ana-
lyzed by Western blotting and established that precipitation of
PTA-1 co-precipitates hDlg; however, the co-association signal
was very faint (data not shown), possibly because the associ-
ated molecules were being lost by prior precipitation with the
cytoskeleton. In support of this, when co-immunoprecipitations
were carried out after pretreatment of the cells with cytocha-
lasin D to disrupt the actin cytoskeleton, clear co-association
was obtained (Fig. 4C).
Next we examined whether hDlg was localized in the GEM
fraction representing membrane rafts and whether its distri-
bution in the transfected Jurkat cells was altered following
TPA treatment or cross-linking of PTA-1 (Fig. 5). PTA-1-trans-
fected Jurkat cells were left untreated or stimulated with TPA
for 3 or 30 min before cell lysis and centrifugation through
sucrose gradients to isolate the GEM fraction. The isolated
GEM fractions were run in SDS-PAGE together with equal
protein loading from the soluble fractions (Fig. 5A) and then
immunoblotted for hDlg and also 4.1G (head), PTA-1, and, as a
control, calnexin. The results (Fig. 5B) indicated that hDlg is a
resident of rafts; the proportion of the protein found in the
GEM fraction did not increase upon treatment of the cells with
TPA but actually appeared to decrease without material be-
coming apparent in the soluble fraction, probably indicating
FIG. 3. Association between PTA-1
and 4.1G in PTA-1-transfected CHO
cells. A, confocal analysis was performed
on the PTA-1-transfected CHO cells la-
beled by indirect immunofluorescence for
PTA-1 with the mouse mAb LeoA1 (green)
and either the 4.1G-Head or 4.1G-Tail af-
finity-purified rabbit antibodies (red). B,
immunofluorescent images obtained from
the PTA-1-transfected CHO cells, co-
stained for actin with phalloidin (green)
together with PTA-1 (mAb LeoA1) and
4.1G (rabbit Head antibody) or co-stained
for DAF (mAb VIIIA7) before or after
treatment of the cells with 2 M cytocha-
lasin D for 60 min at 37 °C prior to fixa-
tion. DMSO, Me2SO. C, CHO transfec-
tants were cross-linked with the indicated
antibodies as described in the legend to
Fig. 1A. Following centrifugation of the
post nuclear supernatants at 14,000  g
for 15 min, immunoblot (IB) analyses
were then performed on the insoluble pel-
let (I) and soluble fraction (S).
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loss of hDlg to the pelleted cytoskeleton. In these assays, both
4.1G and PTA-1 were identified predominantly in the GEM
fractions, whereas calnexin located to the soluble fractions (Fig.
5B). Experiments using PTA-1 cross-linking in which the cy-
toskeletal pellet also was analyzed showed that hDlg was
prominent in this fraction as well as the GEM fraction, al-
though the relative distribution of hDlg was not altered by
cross-linking (data not shown).
The PDZ-binding Peptide at the Carboxyl Terminus of PTA-1
Influences Binding to Multiple Isoforms of 4.1G—As we noted
above, the cytoplasmic tail of PTA-1 can be phosphorylated by
PKC after treatment of Jurkat cells or platelets with TPA. The
residue that is phosphorylated in this way was identified by
Shibuya et al. (59) as serine 329 toward the carboxyl terminus
of PTA-1, within the last 8 residues (FS329RRPKTRV) and
adjacent to the putative PDZ-binding peptide identified by us.
Shibuya et al. (59) mutated this serine residue to phenylala-
nine (Ser 3 Phe) and recorded that this mutation abrogated
PTA-1 phosphorylation in response to TPA treatment of trans-
fected murine thymoma cells and also that these cells were no
longer able to mediate PTA-1-mediated cell adhesion; the au-
thors concluded from these data that phosphorylation of Ser329
plays a critical role in PTA-1-mediated adhesion and signaling.
We therefore tested whether Ser329 might be implicated in
PTA-1 binding to 4.1G. Table I shows a representative yeast
two-hybrid binding analysis of the interaction between the
CTD of protein 4.1G, the cytoplasmic region of PTA-1, and
mutations of PTA-1 in which Ser329 was mutated to either
phenylalanine (Ser3 Phe) or alanine (Ser3 Ala). As shown in
Table I, measured in -galactosidase units, it is apparent that
substitution of the serine at 329 with phenylalanine reduced
the strength of binding in this assay but still permitted strong
binding to occur. Substitution of this serine residue with ala-
nine did not significantly reduce the PTA-1–4.1G interaction.
From these analyses, we conclude that whereas Ser329 within
PTA-1 may be implicated in binding to the CTD of protein 4.1G,
such involvement is more likely to result from the conformation
of PTA-1 in this region rather than an involvement of serine
phosphorylation, since the bulky phenylalanine residue caused
more disruption than alanine as a substitute. In support of this
interpretation, we found that substitution of Ser329 with aspar-
tate (Ser 3 Asp) to mimic phosphoserine did not alter the
strength of PTA-1–4.1G interaction in the -galactosidase as-
say (data not shown). It is interesting to note that the Ser 3
Phe substitution that still binds to CTD of 4.1G in the context
of the PTA-1 cytoplasmic tail now has the sequence FFRR,
similar to the FFKR sequence within the  subunit of LFA-1
that is central to the regulation of integrin adhesive function
(69, 70); should this region be directly implicated in the PTA-
1–4.1G binding interaction, then it is possible that LFA-1 also
could bind to the CTD of 4.1G.
Intermolecular binding by members of the ternary complex
FIG. 4. PTA-1 associates with hDlg. A, fluorograph of 35S-labeled
proteins precipitated with GST alone, GST-PTA-1 fusion protein, or
GST-PTA-1 fusion protein lacking the three carboxyl-terminal amino
acid residues (TRV). For the pull-down assay, Nonidet P-40 lysates
were prepared from Jurkat cells biosynthetically labeled with [35S]cys-
teine/methionine, either from resting cells or after overnight treatment
with TPA. The arrow and arrowheads indicate three protein species of
interest. B, Jurkat cells were treated with TPA for 2 h before lysis with
radioimmune precipitation assay. Cell lysates were used in pull-down
assays against either GST, GST-PTA-1, GST-PTA-1 in vitro phospho-
rylated with PKC, or GST-PTA-1TRV, and samples were analyzed for
hDlg association by immunoblotting (IB). C, hDlg co-immunoprecipi-
tated with PTA-1. Jurkat-PTA-1 permanent transfectants were stimu-
lated with TPA for 2 h and treated with cytochalasin D, and the soluble
digitonin lysate was incubated with anti-PTA-1 mAb (LeoA1) or control
mAb and RAM-Sepharose beads. Immunoprecipitated proteins were
immunoblotted for PTA-1 and hDlg. The lysate sample represents 1% of
the total lysate.
FIG. 5. Localization of PTA-1, 4.1G, and hDlg in the GEM frac-
tion. Jurkat-PTA-1 transfected cells were treated with TPA for the
indicated times and subjected to cold Triton X-100 lysis, and the GEM
fraction was separated by centrifugation through a sucrose gradient.
Equivalent total protein from each of the GEM and soluble (SOL)
fractions were run on SDS-PAGE and transferred to nitrocellulose. A,
Ponceau S staining of the membrane illustrating equal protein loading.
B, the membrane illustrated in A was subjected to immunoblotting (IB)
analysis for 4.1G-Head, PTA-1, and hDlg. These three proteins were
seen to be enriched in the GEM fraction, whereas a control blot for
calnexin showed enrichment in the soluble fraction.
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of erythrocytes, between 4.1R, the MAGUK, p55, and the trans-
membrane protein, glycoprotein C, is interdependent and dy-
namic; for example, the affinity of binding between glycophorin
C and p55 is increased by an order of magnitude by 4.1R in in
vitro binding assays (43). Therefore, we utilized the GST fusion
proteins PTA-1 and PTA-1TRV and also in vitro phosphoryl-
ated GST-PTA-1 in pull-down assays immunoblotted for 4.1G
to determine whether the putative PTA-1-hDlg-4.1G complex
might be similarly interdependent (Fig. 6).
For these experiments, we used lysates from Jurkat cells
that had been left untreated or stimulated for 3 min, 10 min,
2 h, or overnight with TPA. Initially, we concentrated on ex-
amining immunoblots of the higher molecular weight material,
around the major 4.1G 170-kDa isoform identified in whole cell
lysates. An example of these blots is shown in Fig. 6A, and
similar results were obtained by immunoblotting with the “tail”
antibody from lysates from both unstimulated and TPA-stim-
ulated Jurkat cells (data not shown). It is apparent that
whereas there is a degree of specific pull-down by the PTA-1
fusion proteins compared with GST alone, there are no differ-
ences between PTA-1 and PTA-1TRV; nor is there any rela-
tive enrichment of this 4.1G isoform in the pull-downs com-
pared with the total lysate.
A totally different profile was obtained when we examined
the pull-downs of lower molecular weight isoforms of 4.1G (Fig.
6B). Several bands were prominent in the PTA-1 fusion protein
pull-downs that were absent in the GST-alone track, and some
were apparently greatly enriched compared with the whole
lysate blot. The arrowheads in Fig. 6B point to bands that were
consistently seen to be enriched in the PTA-1 fusion protein
pull-downs; these bands were identified with both the “tail”
antibody (Fig. 6B) and the “head” antibody (data not shown),
indicating that they represent 4.1G isoforms and not proteo-
lytic breakdown products, and each of the identified isoforms
appeared to be equally represented in lysates from unstimu-
lated or TPA-stimulated Jurkat cells (Fig. 6B, a and b). Of
particular interest were the bands identified at around 55 and
35 kDa (asterisk on arrowhead in Fig. 6B). The isoform at 55
kDa was poorly represented in the total cell lysates and
strongly precipitated by each of the PTA-1-GST fusion proteins,
but the pull-down with PTA-1TRV yielded more of this prod-
uct than native or phosphorylated PTA-1 (Fig. 6B). This result
perhaps indicates that interaction between PTA-1 and a PDZ-
containing protein reduces the association between PTA-1 and
the 55-kDa isoform of 4.1G. The opposite was the case with the
35-kDa isoform pulled down by native and phosphorylated
PTA-1 but not by PTA-1TRV. In this instance, the binding of
TABLE I
Quantitative yeast two-hybrid analysis of the interaction between
mutations of PTA-1 and the CTD of 4.1G
S. cerevisiae HF7c cells were co-transformed as described under “Ex-
perimental Procedures.” Protein interactions were tested by growth in
selective liquid SD medium lacking Trp for the single transformants,
Leu and Trp (LT) for the double transformants, or Leu, Trp, and His
with the inclusion of 3-aminotriazole (LTH) for higher stringency and
then quantified using a liquid -galactosidase assay. The strong inter-
action between the cytoplasmic tail of PTA-1 and the 4.1G CTD under
both selective conditions was decreased with Ser 3 Phe mutation and
to a lesser degree in the Ser3 Ala mutation, but binding to the 4.1CTD
was still significant and well above levels of activation using the control
activation domain pTD1 plasmid. The -galactosidase assay was per-
formed in triplicate with the values presented as the mean  S.E.
Sample -Galactosidase units
PTA1 alone 0.99  0.22
Ser 3 Phe alone 0.62  0.40
Ser 3 Ala alone 0.29  0.07
PTA1  4.1G LT 85.41  13.33
Ser 3 Phe  4.1G LT 23.72  3.30
Ser 3 Ala  4.1G LT 70.95  3.81
PTA1  4.1G LTH 216.56  76.49
Ser 3 Phe  4.1G LTH 97.16  12.97
Ser 3 Ala  4.1G LTH 168.01  26.44
PTA1  pTD1 3.34  1.72
Ser 3 Phe  pTD1 10.18  6.03
Ser 3 Ala  pTD1 1.24  0.51
FIG. 6. Binding of PTA-1 to various isoforms of 4.1G is influ-
enced by the three carboxyl-terminal amino acid residues of
PTA-1. A, binding of PTA-1 to the 170-kDa isoform of 4.1G is not
influenced by the terminal TRV peptide. Resting Jurkat cell lysates
were incubated with either GST alone, GST-PTA-1, or GST-PTA-
1TRV, and precipitated proteins were separated by SDS-PAGE and
immunoblotted (IB) with the 4.1G-Head or -Tail rabbit antibodies. The
control lysate sample represents 0.5% of the total lysate. B, the termi-
nal TRV peptide of PTA-1 influences the association with small 4.1G
isoforms. Resting Jurkat cells (a) or Jurkat cells stimulated with TPA
for 2 h (b) were subjected to cold radioimmune precipitation assay lysis
and then incubated with either GST, GST-PTA-1 (wt), GST-PTA-1
phosphorylated with PKC in vitro (PKC), or GST-PTA-1 lacking the
three terminal amino acids (TRV). Resultant proteins precipitated
were run on SDS-PAGE and immunoblotted with the 4.1G-Tail rabbit
antibody. The lysate sample constitutes 1% of the total. The arrow-
heads indicate the 4.1G isoforms that the PTA-1 fusion proteins con-
sistently precipitate. The bands further highlighted with asterisks in-
dicate the influence of the terminal TRV peptide of PTA-1 in the
association with 4.1G isoforms. Note that in a and b in the TRV lane,
there is the false appearance of a band at 35 kDa, caused by the label
bound by the GST protein used in the pull-down diffusing into this
region. C, GST pull-down experiment, as described in A, illustrating the
lower 4.1G isoform pulled down by the GST-PTA-1 fusion protein. Note
that the 4.1G-Head antibody recognizes the lower 4.1G isoform at 35
kDa, which the GST-PTA-1 precipitates, whereas the 4.1G-Tail anti-
body illuminates this band plus a stronger larger band above.
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a PDZ-containing protein may be required for binding to this
small isoform of protein 4.1G. Note that in Fig. 6B, the immu-
noblot of the whole lysate appears to identify a prominent band
in the same position as the 35-kDa isoform pulled down by
PTA-1. However, this band, which actually migrates slightly
slower than the PTA-1-associated band, is not the same
polypeptide, since this band is not illuminated with the “head”
antibody, whereas the associated band is identified by both the
“head” and “tail” antibodies (Fig. 6C). Therefore, this isoform
too represents a minor 4.1G product that is greatly enriched by
binding to PTA-1 in pull-down experiments.
The Amino-terminal Region of 4.1G Binds to PTA-1 from
Activated Cell Lysates—Despite the association between PTA-1
and 4.1G documented in numerous assays above, in repeated
attempts we were unable to demonstrate an association be-
tween PTA-1 from cell lysates and the 4.1G CTD used as a GST
fusion protein. The reasons for this are not clear, but it was not
readily attributable to interference by another binding protein,
since we obtained no detectable direct binding between GST-
PTA-1 and GST-4.1G.CTD in surface plasmon resonance ex-
periments (data not shown). In further pull-down experiments
with GST fusion proteins, we also sought to identify an asso-
ciation between PTA-1 and activated Rap1 by pull-down with
the Rap binding protein (20), followed by immunoblotting for
PTA-1. These also gave a negative result, but for these exper-
iments we had used the GST-4.1G-Head protein as an addi-
tional control and obtained the unexpected result that this
unique domain of 4.1G was able to pull down PTA-1 from
lysates of activated but not resting Jurkat cells (Fig. 7). The
example shown in Fig. 7A shows the pull-down of PTA-1 ob-
tained from Jurkat cells that had been either pretreated with
TPA for 30 h to induce PTA-1 protein expression and then
rested overnight (Nil) before treatment with the anti-PTA-1
mAb (LeoA1) alone, with anti-PTA-1 cross-linked with RAM
antibody, or with TPA to induce activation. Western blotting
for PTA-1 shows that this protein was precipitated by the
GST-4.1G “head” protein after the Jurkat cells had been stim-
ulated by antibody-mediated cross-linking (Fig. 7A, track 10) or
by treatment with TPA (Fig. 7A, track 14). These results indi-
cate that upon activation of the Jurkat cells, PTA-1 undergoes
some change enabling it to bind the amino-terminal region of
4.1G; this change could be in consequence of a direct conforma-
tional change in PTA-1, perhaps mediated by phosphorylation
or lipid association, or by an association between PTA-1 and
another molecule such as hDlg. Alternatively, activation of the
Jurkat cells could cause a conformational change to a PTA-1-
binding protein such that it is no longer able to bind, thus
freeing PTA-1 to bind to the head region of 4.1G. To begin to
discriminate between these different possibilities, we carried
out direct binding experiments between GST-PTA-1 and GST-
4.1G “head” proteins by surface plasmon resonance. The re-
sults obtained from these BIAcore experiments (Fig. 7B) show
that these two GST-fusion proteins can interact directly. From
this, we can conclude that the cytoplasmic tail of PTA-1 can
bind to the “head” region of 4.1G without the requirement for
amino acid modification or binding to an intermediary protein.
Taken together, we believe that the simplest interpretation
of the different 4.1 binding data obtained in this report is that
in the resting cell, PTA-1 constitutively associates with the
CTD of 4.1G. Because of the relative excess of 4.1G protein over
PTA-1 in these cells (witnessed in immunofluorescent staining
and immunoprecipitation experiments (data not shown)),
PTA-1 in the cell lysate is unable to bind exogenously presented
4.1G.CTD in the form of a GST fusion protein. There are likely
also to be conformational constraints, since GST-PTA-1 and
GST-4.1G.CTD did not bind directly in surface plasmon reso-
nance experiments (data not shown); but direct binding was
indicated within the context of yeast cells, and GST-PTA-1 was
able to precipitate multiple isoforms of 4.1G from lysates of
resting Jurkat cells (Fig. 6). Upon cell activation, we propose,
there is induced a conformational change in 4.1G, perhaps
analogous to that which occurs in ERM proteins (38), that
alters the conformation of the CTD of 4.1G and exposes a
PTA-1 binding region in the head domain. These dynamic
associations, together with an association with hDlg, provide a
structural basis for a regulated protein complex at the T cell
surface with links to the cytoskeleton.
DISCUSSION
Here we present evidence for a direct physical association
between a T cell activation antigen, PTA-1, a protein 4.1 family
member, 4.1G, and a MAGUK, human discs large. Since the
related protein 4.1R also binds hDlg (71), it is possible that
PTA-1 forms a ternary complex with 4.1G and hDlg, redolent of
other 4.1-transmembrane protein-MAGUK ternary complexes
that form important functional units serving as a clustering
apparatus at sites of cell-cell communication (41). The reported
physical and functional association between PTA-1 and LFA-1
(59), together with its involvement in the development of cyto-
toxic T cells from their precursors (55), suggests that such a
FIG. 7. PTA-1 associates with the amino-terminal domain
(Head) of 4.1G. A, Jurkat cells were treated with TPA for 30 h to
induce PTA-1 protein and then rested overnight (Nil), treated with the
anti-PTA-1 mAb LeoA1 alone (PTA-1), treated with LeoA1 cross-linked
with rabbit anti-mouse antibody (PTA-1  RAM), or treated with TPA
for 40 min at room temperature (TPA) to induce activation. Cell lysates
were then incubated with GST alone, GST-4.1G-Head (amino-terminal
domain), GST-4.1G-CTD (carboxyl-terminal domain), or GST-RBD
(Rap1 binding domain) and then precipitated with glutathione-Sepha-
rose beads. The protein eluates were separated by SDS-PAGE, trans-
ferred to nitrocellulose, and immunoblotted (IB) for PTA-1. Upon acti-
vation either by cross-linking (PTA-1  RAM) or by TPA stimulation,
PTA-1 associated with the amino-terminal domain of 4.1G (lanes 10 and
14, respectively). B, surface plasmon resonance sensorgram showing
the binding between PTA-1 and the 4.1G-Head domain. Purified GST
alone, GST-PTA-1, and GST-4.1G-CTD were passed over GST-4.1G-
Head- or GST-coupled sensor chips. After subtraction of the weak
binding of the GST fusion proteins to the GST-coupled chip, significant
binding of GST-PTA-1 to the GST-4.1G-Head coupled chip was ob-
served, in comparison with the weak binding of GST-4.1G-CTD. No
binding was observed for GST (data not shown).
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complex may play an important functional role at the immu-
nological synapse. A model incorporating this putative complex
is given in Fig. 8.
There are, however, substantial differences between the mo-
lecular interactions described for the other known ternary com-
plexes involving a transmembrane protein in association with
4.1 proteins and that described here for PTA-1. Thus, in the
best characterized example, involving the transmembrane pro-
tein glycophorin C, the MAGUK, p55, and protein 4.1R, both
the cytoplasmic domain of glycoprotein C and the HOOK do-
main of p55 bind to the FERM domain of 4.1R at adjacent sites
(72). By contrast, the cytoplasmic domain of PTA-1 binds to the
CTD of protein 4.1G, as determined in yeast two-hybrid assays,
and to the amino-terminal domain (ATD) of 4.1G, at least in
activated cells, as shown in GST fusion protein pull-down as-
says and by surface plasmon resonance. Note that the ATD
used in these assays incorporated only the first 115 residues of
4.1G, a region that is unique to this protein 4.1 family member
and does not incorporate any of the downstream FERM domain
(see Fig. 2B). The function of these domains of 4.1 family
members is unknown. The CTD of protein 4.1G has been shown
to bind to the immunophilin-binding protein, FKBP13, that
may function as a molecular chaperone to catalyze the folding
and/or assembly of proteins in the endoplasmic reticulum (73),
and to an intracellular loop of the A1 adenosine receptor (74).
In addition, the CTD of nuclear forms of the paralogues 4.1N
and 4.1R have been demonstrated to bind to and to be impli-
cated in the functioning of a nuclear GTPase that regulates
phosphatidylinositol 3-kinase kinase activity and the nuclear
mitotic apparatus protein, respectively (75, 76). The ATD of
4.1R contains a high affinity calcium-dependent calmodulin
binding domain (77); however, this region of 4.1G shares only
23% identity over the 17 residues involved (73); therefore, it is
unclear whether such a functional domain is present in 4.1G.
To our knowledge, PTA-1 is the first protein identified as bind-
ing the unique head region of 4.1G.
We show that PTA-1 also binds the MAGUK, hDlg, probably
through binding to a PDZ domain. This finding potentially
places PTA-1 as a membrane anchor for a large multimeric
complex incorporating a diversity of functional entities, each
with the capacity to modify the immunological response. hDlg
comprises a series of modules that bind to a bewildering num-
ber of proteins. The protein additionally undergoes multimer-
ization that could contribute to clustering (67). The proline-rich
amino-terminal domain of hDlg interacts with Lck protein ty-
rosine kinase. This is followed by three PDZ domains known to
bind the potassium ion channel, Kv1.3, and the tumor suppres-
sor PTEN among others (47, 78); a Src homology 3 domain; and
then a HOOK domain able to bind the FERM domain of 4.1R.
Whether this interaction also occurs between hDlg and 4.1G
has not been established, but this is likely to be the case, since
the FERM domains of these paralogues are highly homologous,
and, at least in epithelial cells, this interaction plays a critical
role in recruiting hDlg to the lateral membrane (52). At the
carboxyl terminus of hDlg is a guanylate kinase-like domain,
the hallmark of MAGUK family members. This domain is en-
zymically inactive and seems to have evolved as a specialized
protein recognition module. The guanylate kinase domain of
hDlg has been shown to bind to the Rap1 GTPase-activating
protein known as SPA-1, SPAL, or SPAR that plays a role in
regulating cell adhesion (44, 45, 79). This domain also binds to
the kinesin-like motor protein known as GAKIN, and in T
lymphocytes (Jurkat T cells) the hDlg-GAKIN complex moves
from the cytoplasm to the lymphocyte cap, presumably along
microtubules, upon stimulation by antibody-mediated cross-
linking to induce cell activation (46). GAKIN-mediated trans-
port of hDlg is dependent upon its molecular motor domain,
and Asaba et al. (51) have proposed that hDlg is a cargo mol-
ecule of GAKIN that is directed to specialized sites of cell-cell
contact by the microtubule plus end-directed motor protein.
Adding to the potential size of the complex is the range of
partners known to associate with protein 4.1 family members
by binding to the FERM domain; these include Ca2-calmodu-
lin, phosphatidylinositol 4-phosphate, and phosphatidyl 4,5-
biphosphate and transmembrane proteins such as CD44 (41),
and it has been suggested that this domain is likely also to bind
several GTPase protein regulators (41, 80).
The FERM domains of 4.1G and 4.1R share 76% identity
(65); therefore, it is likely that 4.1G also has several binding
partners in this region. Whether any of these 4.1/hDlg binding
molecules also co-associate with a PTA-1 complex is not known,
but since several can be located to rafts at the immunological
synapse, it seems possible that such multimeric complexes will
be formed. This possibility raises the interesting questions of
where the complex(es) are formed and how the existence of
such a PTA-1-associated complex might influence LFA-1 bind-
ing and signaling.
We favor the hypothesis that the 4.1G-associated complexes
are formed at recycling rafts found in the Golgi region (81).
Parra et al. (65) demonstrated that 4.1G is concentrated in the
perinuclear region in transfected COS cells, and we show here
that 4.1G, hDlg, and PTA-1 are concentrated in the GEM
fraction that represents raft material. The composition of the
FIG. 8. Model of the dynamic assembly of the LFA-1-PTA-1
complex. In the resting state, PTA-1 forms an association with the
CTD of the FERM superfamily protein 4.1G. 4.1G consists of a unique
amino-terminal extension (NT), the three-lobed FERM domain, a spec-
trin-actin (SA) binding domain, and a CTD. As shown, 4.1G is possibly
present in a closed conformation, resulting from an intramolecular
interaction between its amino and carboxyl termini which is character-
istic of the FERM superfamily proteins. The LFA-1 integrin is present
in an inactive form and not associated with PTA-1. Upon activation, a
ternary complex between PTA-1, hDlg, and 4.1G is formed where the
cytoplasmic tail of PTA-1 now associates with the amino-terminal ex-
tension domain of 4.1G, and its carboxyl-terminal PDZ-binding peptide
binds to one of the PDZ modules in the MAGUK protein, hDlg. The
HOOK (H) domain of hDlg in turn associates with the FERM domain of
4.1G. In this model, the CTD and SA binding domain of 4.1G are now
exposed and may facilitate further molecular interactions, such as the
association with F-actin. Activated LFA-1 may also physically associate
with the PTA-1 complex via an interaction between their respective
extracellular domains. Intracellularly, this complex may be regulated
by interaction with the Rap1-GTPase and its related signaling compo-
nents. The integrin -chain cytoplasmic domain possesses a consensus
motif that may support binding of the Rap1 effector molecule RapL.
Additionally, the guanylate kinase (GUK) domain of hDlg is known to
bind the Rap1-activating protein, SPA-1. These interactions are sug-
gested to play a regulatory role in the assembly of the LFA-1-PTA-1
complex (diagram adapted from Ref. 52). The NH2-terminal domain of
hDlg is not shown for simplicity. See “Discussion” for further details.
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raft material would promote clustering and protein-protein
associations, and, in association with growing microtubules,
the complex could be delivered to specific areas at the leading
edge (82), perhaps driven by GAKIN. Alonso and Milla´n (83)
have recently provided a detailed consideration of the role of
rafts in the assembly and trafficking of signaling complexes in
T cells; they note that in these cells, the uropod is rich in rafts
that might provide a reservoir for subsequent delivery of raft
proteins and lipids to the immunological synapse. Notably,
TCR engagement drives the transport of gangliosides and Lck
(which is known to associate with hDlg) (47) from an intracel-
lular store to the plasma membrane and the translocation of
Lck-associated PKC to rafts at the immunological synapse. Of
interest, ICAM-3 that accumulated in the uropod of polarized T
cells after delivery by binding to the FERM domain of moesin
(34) is subsequently targeted to sites of immune cell-cell con-
tact by an unknown mechanism (10). The similarities between
the FERM domains among 4.1 superfamily members might
allow ICAM-3 at the uropod to interact with 4.1G for transport
back to the leading edge. Similarly, the FERM domain of 4.1G
potentially could interact with the  subunit of LFA-1 (29),
thereby providing a mechanism for the documented association
with PTA-1 (59). However, Shibuya et al. (59) noted that PTA-1
associated specifically with LFA-1 after T cell activation rather
than with all 2 integrins as would be the case if 2 interacted
with the 4.1G FERM domain. In this regard, the recent work of
Katagiri et al. (84) may be instructive. These authors identified
a Rap1 effector termed RAPL that binds to Rap1 and also to
LFA-1 dependent upon two charged residues just downstream
of the FFKR motif in the integrin  subunit. Importantly, they
showed that in T cells RAPL was localized to a perinuclear
region in the cytoplasm near the microtubule organizing cen-
ter. LFA-1 also was found localized at this site, and upon T cell
stimulation both RAPL and LFA-1 migrated together to the
immunological synapse at the leading edge. Mutation of the
two charged residues in LFA-1 that interact with RAPL inhib-
ited the redistribution of LFA-1 alone. Katagiri et al. (84) also
note that Rap1 activation begins in the perinuclear region and
suggest that Rap1 and RAPL may be involved in the loading
and direction of cargo molecules, including LFA-1, from the
perinuclear region to the immunological synapse at the leading
edge following T cell activation.
How this redistribution of the complex is achieved is not
known, but we suggest that the PTA-1–4.1G-hDlg complex
may be implicated. In addition to the activation-induced asso-
ciation between PTA-1 and LFA-1 (59), we show here that
T-cell activation also induces an association between PTA-1
and Rap1 in membrane fragments and that both are contained
within rafts (Fig. 1). Of interest, deletion of the first 100 resi-
dues of RAPL resulted in a protein (RAPN) that failed to bind
Rap1-GTP yet acted as a dominant-negative inhibitor of Rap1
activation-induced adhesion and also inhibited the redistribu-
tion of LFA-1 (84). We note that contained within this region of
RAPL is the sequence REKNCLGMKLSED that approximates
to a consensus 4.1 binding sequence RXKX0–4GXYX3E (where
X represents any amino acid) identified by Hoover and Bryant
(41). Whether these proteins can associate awaits further
study, but the existence of such a complex together with hDlg
and GAKIN would provide a satisfactory explanation for sev-
eral aspects of LFA-1 trafficking and regulation.
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